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Ginkgo biloba extracts (GBEs) have been recommended to improve cognitive function
and to prevent cognitive decline, but earlier evidence was inconclusive. Here, we
evaluated all systematic reviews of GBEs for prevention of cognitive decline, and
intervention of mild cognitive impairment (MCI) and dementia. Six databases from their
inception to September 2015 were searched. Ten systematic reviews were identified,
including reviews about Alzheimer’s disease (n = 3), about vascular dementia (n = 1),
about both Alzheimer’s disease and vascular dementia (n = 2), about Alzheimer’s
disease, vascular dementia and mixed dementia (n= 3), and a review about MCI (n = 1).
Based on the overview quality assessment questionnaire, eight studies were scored
with at least 5 points, while the other two scored 4 points and 3 points, respectively.
Medication with GBEs showed improvement in cognition, neuropsychiatric symptoms,
and daily activities, and the effect was dose-dependent. Efficacy was convincingly
demonstrated only when high daily dose (240mg) was applied. Compared with placebo,
overall adverse events and serious adverse events were at the same level as placebo,
with less adverse events in favor of GBE in the subgroup of Alzheimer’s disease patients,
and fewer incidences in vertigo, tinnitus, angina pectoris, and headache. In conclusion,
there is clear evidence to support the efficacy of GBEs for MCI and dementia, whereas
the question on efficacy to prevent cognitive decline is still open. In addition, GBEs seem
to be generally safe.
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INTRODUCTION
Cognitive decline is a major social problem of public health (Hugo and Ganguli, 2014; Hill et al.,
2015). Cognitive decline includes mild cognitive impairment (MCI) and dementia (Howieson,
2016; Jørgensen et al., 2016; Mormino and Papp, 2016; Ströhle and Rapp, 2016; Thomas, 2016).
MCI is characterized by a slight but noticeable decline in cognitive function, which is regarded as
a symptomatic stage before progression to dementia (Budson and Solomon, 2012; Thung et al.,
2015; Fernández-Blázquez et al., 2016; Petersen, 2016). MCI is further categorized into MCI due to
Alzheimer’s disease (AD) andMCI due to other causes. Dementia is a chronic acquired progressive
mental retardation syndrome (Damiani et al., 2014; Noel-Storr et al., 2014; Ihl et al., 2015; Mitchell,
2015; Ngo and Holroyd-Leduc, 2015; Wang et al., 2016). The causes include AD, vascular dementia
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(VD), and mixed dementia (Montine et al., 2014; Altamura
et al., 2016). AD is the most common neurodegenerative
disease, and generally begins with mild memory problems,
progressing to the development of multiple cognitive and
functional impairment within a few years (Brooker et al., 2014;
Dubois et al., 2014; Aygün and Güngör, 2015; Apostolova, 2016;
Wood, 2016). VD is a severe cognitive dysfunction syndrome
caused by ischemic stroke, hemorrhagic stroke, and cerebral
vascular disease with low cerebral perfusion which leads to
the impairment of memory, cognition, and behavior (Tsivgoulis
et al., 2014; O’Brien and Thomas, 2015). Mixed dementia means
that both AD and VD occur in one patient (Moore et al.,
2014; Bogolepova, 2015; Kim et al., 2016). Currently, more
than 46 million people live with dementia worldwide, and
the number is estimated to increase to 131.5 million by 2050
(Prince et al., 2015). Dementia also has a huge economic impact.
The total worldwide cost was US$ 818 billion in 2015, US$
604 billion in 2010, and is estimated to be 1 trillion in 2018
(Prince et al., 2015).
The treatment for dementia and MCI is still symptomatic
(Fitzpatrick-Lewis et al., 2015). Up to now, no disease-
modifying therapy has been available (Kennedy and Sud,
2014). Cholinesterase inhibitors increase the concentration of
neurotransmitter in the brain and improve memory (Rockwood
et al., 2013; Yáñez and Viña, 2013; Chen et al., 2016);
NMDA receptor antagonists reduce neurotoxicity through
inhibiting excitatory amino acid receptors (Newport et al.,
2015; Schmidt et al., 2015); other drugs such as Serotonergic
agents, Dopamine blocking agents, Benzodiazepines alleviate
specific other symptoms (Schneider et al., 2014; Deardorff
et al., 2015). Thus, there are multiple alternative strategies
with moderate efficacy for some patients for a limited amount
of time.
Ginkgo biloba extracts (GBEs) are widely used for
various kinds of disorders, including cognitive dysfunctions,
headache, tinnitus, vertigo, inattention, mood disturbances,
cardiovascular diseases, and coronary heart disease (DeFeudis
and Drieu, 2000). Ginkgo biloba contains flavonoids, terpene
lactones, and ginkgolic acids (Oken et al., 1998). GBEs
have been demonstrated to have antioxidative activities,
to increase tolerance to hypoxia, and to improve blood
rheology by increasing the flexibility of cellular blood
components, thus enhancing microcirculation; affecting
neurotransmitter levels; enhancing neuroplasticity; prevention
of brain edema; and neuroprotection (DeFeudis and Drieu,
2000; Tchantchou et al., 2007, 2009; Fehske et al., 2009;
Yoshitake et al., 2010; Altamura et al., 2016). GBEs have
been widely used in the treatment of dementia for decades
now (Weitbrecht and Jansen, 1986; Oken et al., 1998). Some
systematic reviews have been conducted to assess GBEs in
prevention and treatment of MCI and dementia (Janssen
et al., 2010; Wang et al., 2010; Weinmann et al., 2010;
Yang et al., 2011, 2014, 2016; Hu et al., 2013; Jiang et al.,
2013; Gauthier and Schlaefke, 2014; Tan et al., 2015). To
provide an overview over the large amount of available data,




Systematic reviews and meta-analyses of GBEs for prevention,
MCI, and dementia were searched in six databases from their
inception to September 2015. The databases included Chinese
biological medical literature database, Web of science, Pubmed,
Chinese Wanfang data, Chinese VIP information, and Chinese
national knowledge infrastructure. The search terms used were
[“Ginko biloba” OR (“Ginkgo biloba” AND extract) OR “EGb
761”] AND (“cognitive function decline” OR “mild cognitive
impairment” OR “mixed dementia” OR “Alzheimer’s disease”
OR “vascular dementia”) AND (“systematic review” OR “meta-
analysis”) in English and Chinese. The reference lists of all
relevant articles were searched for additional studies.
Inclusion Criteria and Exclusion Criteria
Studies that met all of the following criteria were included: (i)
the articles were systematic reviews and/or meta-analysis; (ii) the
publications reported the use of GBEs for prevention of cognitive
function decline, or for intervention of MCI, and dementia,
including AD, VD, or mixed dementia; (iii) studies were limited
to humans.
Studies were excluded if they were any of the following: (i)
systematic reviews evaluating other Chinese herbal medicine or
mixed treatments; (ii) non-systematic reviews, comments, and
overviews.
Study Selection and Data Collection
All articles were read by two independent reviewers (YBZ, HFZ)
and data from the articles were extracted and validated according
to predefined criteria. The following details of the article were
extracted from the included studies: (1) first author’s name and
the publication year; (2) the types of diseases, number of primary
studies, and quality of primary studies; (3) the conclusions and
meta analyses of primary studies, and the nature of the extracts
of Ginkgo biloba; (4) the overall scores and each items on
OQAQ; (5) quality assessment, quality of randomized controlled
trials, inclusion criteria and exclusion criteria of primary studies.
Data for meta-analyses were based on the reported summary
statistics for each study. Disagreements regarding inclusion and
quality were settled through discussion or consultation with the
corresponding author.
Quality Assessment
Two investigators independently (YBZ and HFZ) assessed the
methodological quality of all included systematic reviews by
using the overview quality assessment questionnaire (OQAQ)
(Al Faleh and Al-Omran, 2009). The OQAQ is composed of 10
questions, graded on a 7-point scale. Questions 1–9, which were
answered with “adequate,” “inadequate,” or “not mentioned,”
addressed the five methodological aspects of systematic reviews,
including search strategy, study selection, validity assessment,
data analysis, and conclusions. Only the answer “adequate”
receives a positive score, while “inadequate” or “not mentioned”
scored 0 point. Each of questions 1–4 and 9 values 1 point, while
each of questions 5–8 is 0.5 points. The final question 10 is to
conclude the whole points of the scientific quality of these reviews
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FIGURE 1 | Flow Diagram of included systematic reviews.
we rate. A score of three or less was regarded as indicative of
extensive or major flaws and a score of 5 or more as suggesting
minor or minimal flaws.
RESULTS
Description of the Screening Process
The search strategy yielded 229 potentially relevant hits. After
removal of duplicates, 195 records remained. Through screening
titles and abstracts, we excluded 160 papers. In the remaining 35
papers, 25 papers were excluded with at least one of following
reasons: (1) not relevant to dementia or MCI (n = 5); (2) not
relevant to GBEs (n= 5); (3) not a systematic review (n= 11); (4)
not a meta-analysis based on clinical articles (n = 1); (5) animal
studies (n= 2); (6) duplicated publication (n= 1). Ultimately, 10
eligible studies were selected (Figure 1).
Study Characteristics
The 10 systematic reviews included were published between 2010
and 2015. Among them, 9 systematic reviews were published in
English and 1 systematic review in Chinese (Jiang et al., 2013).
7 first authors of the 10 systematic reviews were from China
(Wang et al., 2010; Yang et al., 2011, 2014, 2016; Hu et al., 2013;
Jiang et al., 2013; Tan et al., 2015), 1 from Canada (Gauthier
and Schlaefke, 2014), and 2 from Germany (Janssen et al., 2010;
Weinmann et al., 2010). The 10 systematic reviews included
reviews about Alzheimer’s disease (n = 3), about vascular
dementia (n = 1), about both Alzheimer’s disease and vascular
dementia (n = 2), about Alzheimer’s disease, vascular dementia
and mixed dementia (n = 3), and a review about MCI (n =
1) (Table 1). The inclusion criteria, the quality of randomized
controlled trials, exclusion criteria, and the quality assessment in
studies are presented inTable 2. Four systematic reviews (Janssen
et al., 2010; Hu et al., 2013; Gauthier and Schlaefke, 2014; Yang
et al., 2014) assessed methodological quality according to the
Jadad score. Five systematic reviews (Wang et al., 2010; Yang
et al., 2011, 2016; Jiang et al., 2013; Tan et al., 2015) used the
Cochrane Collaboration guidelines to evaluate methodological
quality. The remaining systematic review (Weinmann et al.,
2010) assessed methodological quality according to the modified
Cochrane Collaboration guidelines. The randomized controlled
trials (RCTs) compared GBEs with either placebo or Western
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conventional medicine (WCM) in patients with MCI, VD, AD,
and/or mixed dementia. The quality of randomized controlled
trials in 7 studies (Wang et al., 2010; Weinmann et al., 2010; Jiang
et al., 2013; Gauthier and Schlaefke, 2014; Yang et al., 2014, 2016;
Tan et al., 2015) are good, while moderate in 2 studies (Janssen
et al., 2010; Yang et al., 2011) and poor in 1 study (Hu et al.,
2013). Seven systematic reviews (Wang et al., 2010; Weinmann
et al., 2010; Yang et al., 2011, 2016; Jiang et al., 2013; Gauthier
and Schlaefke, 2014; Tan et al., 2015) reported inclusion criteria
and exclusion criteria, while three (Janssen et al., 2010; Hu et al.,
2013; Yang et al., 2014) reported inclusion criteria only. Key data
of included systematic reviews are summarized in Tables 1, 2.
Assessing the Quality of Systematic
Reviews
According to OQAQ scores, the quality of these systematic
reviews varied. Nine studies included (Janssen et al., 2010; Wang
et al., 2010; Weinmann et al., 2010; Yang et al., 2011, 2014, 2016;
Jiang et al., 2013; Gauthier and Schlaefke, 2014; Tan et al., 2015;
Table 3) were considered to have only minor or minimal flaws,
i.e., scored with at least 5 points on the OQAQ. One systematic
review was seriously flawed and scored 3 points only (Hu et al.,
2013; Table 3). Although the review by Yang et al. (2016) received
an OQAQ score of 6, this study is not useful because in the
analysis it seems that no careful distinction between MCI and
dementia was performed and because some important trials
reporting on AD subgroups are missing (e.g., Kanowski and
Hoerr, 2003; Napryeyenko et al., 2009).
Effectiveness
Prevention
Only two systematic reviews mentioned prevention of cognitive
function decline and the results were not significant. In one
review (Yang et al., 2014), the preventative effect of AD were
studied in two studies (DeKosky et al., 2008; Vellas et al., 2012),
while in the other review (Yang et al., 2016), only one study was
included (Vellas et al., 2012). However, in the study by DeKosky
et al. (2008) an extremely low compliance was a serious issue; in
both trials the overall conversion rate to dementia was too low
to draw conclusions on the efficacy, as both studies were highly
underpowered. In addition, the study by Vellas et al. (2012)
was inconclusive. Not only was there a significantly lower rate
of progression to AD in the prospectively specified subgroup
of subjects who were on drug for at least 4 years, there was
also a problem with the pre-specified statistical test which was
chosen assuming proportional hazards. When this assumption
turned out wrong, because hazards were found to increase
during the study period, a post-hoc analysis was performed
by Scherrer et al. (2015) which demonstrated a significantly
lower rate of progression to AD in the Extract Ginkgo biloba
number 761 (EGb 761) R©-treated subjects when an appropriate
statistical test was applied that accounts for the non-proportional
hazards. Hence, the question whether GBE can prevent dementia
or cognitive remains to open and needs to be examined in
the future.
MCI
(1) Activities of daily living (ADL): There were no significant
difference betweenGBEs plusWCMandWCMalone (Yang et al.,
2016). (2) Cognition function: Both GBEs alone and GBEs plus
WCM were more effective than WCM (Yang et al., 2016).
Dementia
(1) Global clinical assessment: Two systematic reviews (Wang
et al., 2010; Gauthier and Schlaefke, 2014) indicated that EGb 761
was better than placebo. Gauthier and Schlaefke (2014) further
demonstrated that EGb 761 was dose-dependently effective, with
and high daily dose (240 mg) of EGb 761 with better efficacy
compared to low dose (120 mg). (2) ADL: One systematic review
(Tan et al., 2015) indicated that GBEs could improve ADL in
dementia patients, but another one (Weinmann et al., 2010) did
not show such effect, because that analysis could not include
several of the more recent and successful trials. Jiang et al.
(2013) specifically demonstrated that EGb 761 could improve
ADL in relatively young (age <75 years) patients but not in
those older than 75. However, only two trials were included in
the age group above 75 years. When 4 trials were included in
the analysis of old patients, a clear beneficial effect of EGb 761
could be demonstrated by Kasper (2015). Moreover, Jiang et al.
(2013) inappropriately included the trials by van Dongen et al.
(2003) and McCarney et al. (2008). van Dongen et al. (2003)
included a mixed population of subjects with aging-associated
memory impairment (AAMI) and dementia. Most patients had
AAMI, i.e., they had–by definition–no impairment of ADL and
therefore they could hardly improve significantly in ADL. In
the study by McCarney et al. (2008) substantial proportions
of the Ginkgo and placebo groups (about one third) were on
cholinesterase inhibitors. Effective treatment with cholinesterase
inhibitors may decrease the chance and the extent of further
improvement by GBE. Moreover, 25% of the patients in the
Ginkgo group, but only 10% of the patients in the placebo
group had been treated with Ginkgo before enrollment. Those
treated with GBE before are certainly less likely to show marked
further improvement during the study. Furthermore, the study
was seriously underpowered due to recruitment problems and
due to the split of both groups to sub-groups with minimal
and extensive follow-up, variances were particularly large, which
further decreased statistical power. The inappropriate choice of
trials for inclusion and the exclusion was seriously flawed and
trials that enrolled different patients are essential for a review
to mislead to the correct conclusion with regard to efficacy in
a specific disorder. Two systematic reviews (Jiang et al., 2013;
Gauthier and Schlaefke, 2014) demonstrated that the effects
of high daily dose (240 mg) on ADL were more significant
than that of placebo. Although one systematic review (Gauthier
and Schlaefke, 2014) indicated that relatively low daily dose
(160 or 120 mg) of GBEs could improve ADL of dementia
patients, another one (Jiang et al., 2013) had opposite results.
(3) Cognition function: Two systematic reviews (Weinmann
et al., 2010; Tan et al., 2015) indicated that GBEs could improve
cognition function in dementia patients. Furthermore, both two
systematic reviews (Jiang et al., 2013; Gauthier and Schlaefke,
2014) indicated that the effects on cognition function were
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dose-dependent and relatively high daily dose (240 mg) of
GBEs could improve cognition function in dementia patients.
Jiang et al. (2013) specifically indicated that EGb 761 could
improve cognition function of relatively young (age <75 years)
people but not in those older than 75. However, only two
trials were included in the age group above 75 years. When
four trials were included in the analysis of old patients, a clear
beneficial effect of EGb 761 could be demonstrated by Kasper
(2015). (4) Neuropsychiatric and behavioral symptoms (NPS):
GBEs improve neuropsychiatric symptoms, including depression
(Weinmann et al., 2010; Jiang et al., 2013; Gauthier and Schlaefke,
2014; Tan et al., 2015), there was a significant difference in
favor of 240 mg/day EGb761 (p < 0.00001) when assessing
efficacy regarding improvement of neuropsychiatric symptoms
(Tan et al., 2015).
AD
(1) Global clinical assessment: Two systematic reviews (Gauthier
and Schlaefke, 2014; Yang et al., 2016) indicated that the
effectiveness of EGb 761 was better than that of placebo. Yang
et al. (2016) indicated that there was no significant difference
comparing EGb 761 withWCM; however, this study is not useful
because of its shortcomings explained above. (2) ADL: Four
systematic reviews (Janssen et al., 2010; Weinmann et al., 2010;
Yang et al., 2014; Tan et al., 2015) indicated that GBEs were
effective for improving ADL. The effects on ADL were dose-
dependent and relatively high daily dose (240 mg) of GBEs were
more effective than placebo (Janssen et al., 2010). Yang et al.
(2016) indicated that the effectiveness of GBEs was better than
that of placebo but not WCM. However, due to the serious
concerns regarding the review by Yang et al. (2016) mentioned
above, such conclusions should be taken with a grain of salt. An
additional mistake in the review by Yang et al. (2016) is that
in the study by Maurer et al. (1997), there was no significant
difference in the Syndrom Kurz Test (SKT) favoring EGb 761 R©.
Actually, there was a significant difference in the SKT and
there was a non-significant difference in the Alzheimer’s disease
assessment scale-cognitive subscale (ADAS-cog), both in favor
of EGb 761 R©. The size of the change in the ADAS-cog was
as expected from the size of the change in the SKT (both
correlate very well), but due to the variance this difference was
not significant for the ADAS-cog in the very small number of
patients. In the study by Mazza et al. (2006), there also was a
significant difference in favor of active treatment in the SKT, but
not in the MMSE. The MMSE is a screening test for cognitive
impairment and dementia and has never been validated as an
outcome measure for treatment trials in dementia. Actually, in
the study by Mazza et al. (2006) the difference in MMSE changes
between donepezil and placebo was not significant either. These
issues demonstrate again that assessing the quality of a review
always involves a careful evaluation of the quality of the single
trials and their correct representation in the review. (3) Cognition
function: Two systematic reviews (Weinmann et al., 2010; Tan
et al., 2015) indicated that GBEs improve cognition function in
AD patients. (4) NPS: In an earlier analysis that could not yet
take into account the most recent clinical trials, no significant
effect on neuropsychiatric and behavioral symptoms could be
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demonstrated (Weinmann et al., 2010). However, in a more
recent review, a significant effect of EGb 761 on neuropsychiatric
symptoms could be demonstrated (Tan et al., 2015). (5) Quality
of life: Yang et al. (2016) indicated that GBEs for ADwas superior
to placebo as measured by the quality of life questionnaire
for person with dementia (DEMQOL)-proxy quality of life
scale. Janssen et al. (2010) indicated that two trials available
in that domain at the time that review was generated showed
contradictory results. VD (Hu et al., 2013): (1) ADL: GBEs were
as effective for improving ADL of VD patients compared with
WCMs such as donepezil, gamma aminobutyric acid (GABA)-
ergic drugs or other therapies. (2) Cognition function: GBEs
could improve cognition function in VD patients according to
MinimumMental State Examination (MMSE) scores.
Adverse Events
Eight systematic reviews (Janssen et al., 2010; Weinmann et al.,
2010; Yang et al., 2011, 2016; Hu et al., 2013; Jiang et al., 2013;
Gauthier and Schlaefke, 2014; Tan et al., 2015) examined adverse
effects, while the other two (Wang et al., 2010; Yang et al.,
2014) did not. Yang et al. (2011) reported that one patient had
hypersensitivity. Weinmann et al. (2010) concluded that there
was no difference between the GBEs group regarding adverse
events and the placebo group. Janssen et al. (2010) found that,
although the number of patients that discontinued the trial was
higher compared to the placebo group, no evidence for a harmful
effect of GBEs was observed. Interestingly, GBEs potentially
reduce adverse events. Jiang et al. (2013) reported that headache
(RR = 0.74, 95% CI = 0.60–0.92, p < 0.01, total n = 2060);
dizziness (RR = 0.54, 95% CI = 0.30–0.97, p = 0.04, total n =
2060), and tinnitus (RR = 0.39, 95% CI = 0.24–0.65, p < 0.01,
total n= 1323) were significantly less frequent in the GBEs group
than in the control group. There were no significant differences
in the occurrence of respiratory tract infections (RR = 1.09, 95%
CI = 0.78–1.52, p = 0.62, from 4 RCT, total n = 1733), diarrhea
(RR = 0.93, 95% CI = 0.56–1.54, p = 0.77, from 2 RCT, total
n= 810), or blood pressure elevation (RR= 0.73, 95%CI= 0.47–
1.15, p = 0.17, from 3 RCT, total n = 1220) between the GBEs
group and the control group. Tan et al. (2015) indicated that
occurrence of dizziness, tinnitus, headache and angina pectoris
in the GBEs group was lower compared to the placebo group.
Gauthier and Schlaefke (2014) indicated that GBEs have no
increased risk for headache, dizziness, hypertension, tinnitus,
angina pectoris or respiratory tract infection. Yang et al. (2016)
indicated that there was no significant difference in nausea,
dizziness, headache, blood pressure elevation, respiratory tract
infection, dyspepsia, epigastric discomfort, weight loss, agitation,
constipation, diarrhea, dry mouth, and bradycardia between the
GBEs and the placebo group. Hu et al. (2013) reported that there
was no difference in dizziness, headache, rash, insomnia, and
diarrhea between the GBE and the placebo group.
DISCUSSION
Summary of Evidence
Ten systematic reviews were included in the present study. Eight
out of the ten systematic reviews had high quality according to
OQAQ. To our knowledge, this is the first systematic review
for systematic reviews on efficacy and safety of GBEs for MCI
and dementia. Medication with GBEs showed improvement in
cognition and daily activities, and the effect was dose-dependent.
Significant efficacy was only demonstrated when they were
used in high daily dose (240 mg). Compared with placebo,
adverse events were fewer in patients treated with GBE compared
with placebo regarding the symptoms of dizziness/vertigo,
tinnitus, headache, and angina pectoris. GBEs improve cognition
functions but had no effect on ADL in MCI patients. However,
there may be subtle impairment in instrumental ADLs in MCI
patients, and then the scales used in earlier trials were certainly
not sensitive enough to detect the presence or treatment-related
changes in such subtle instrumental ADLs. There is no use
measuring ADLs in patients with MCI or AAMI who have
subtle or no ADL impairment, and then saying there was no
improvement. GBEs improve NPS both in dementia patients and
in the subgroup of AD patients. GBEs improve quality of life but
couldn’t change the progression of AD patients. However, the
effects of GBEs on the progression of AD pathology have never
been studied. Hence, it is not known if GBEs have such a disease-
modifying effect, but what has not been studied cannot just be
denied.
Limitations
Some weaknesses exist in this study. (1) We also included
reviews that did not clearly distinguish between Ginkgo extracts
generated using different extraction methods. Extracts derived
from the same plant can display substantial differences in
composition, efficacy and safety. For instance, differential effects
of EGb 761 have been demonstrated by Itil et al. (1996)
when compared with other Ginkgo extracts. Efficacy of Ginkgo
extracts was only demonstrated for the special extract EGb 761.
(2) Even though most of these systematic reviews have high
quality, the methodology of some primary trials may not be
totally scientific which may result in some contradictory results.
(3) By analyzing systematic reviews rather than clinical trials,
important details of the primary studies may have been lost. (4)
The weakness rested with primary studies. The objective of a
systematic review is to provide a complete, exhaustive summary
of current literature according to presetting a research question.
The most important step is a thorough search of the relevant
literature when conducting a systematic review. Thus, missing
the important literature would undermine. In the present study,
only a few systematic reviews included the large, recent trials by
Ihl et al. (2011) and Herrschaft et al. (2012). Consequently, some
reviews included here lack vital evidence and yielding inaccurate
results.
Implications for Future Research and
Practice
Our study provides a broad summary on all systematic reviews
of GBEs for prevention, MCI and dementia which was essential
for determining the efficacy of multipletherapeutic interventions,
providing an important source for clinical and health policy
decision making, as well as for clinical guidelines. GBEs are
applied to the entire process of dementia, from prevention,
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MCI to dementia severe cases. In addition, GBEs seemed to be
generally safe for clinical application.
Up to now, no drug has been demonstrated to prevent
cognitive function declining and progression to AD in healthy
people. However, in a 20-year long follow-up population-
based study, Amieva et al. (2013) indicated that EGb 761
specifically prevented cognitive decline in a non-demented
elderly population when compared with non-users. Thus, the
long effects of GBEs on preventing cognitive function decline
need to be further confirmed.
One systematic review focused on the MCI, indicating that
there is mixed evidence to support efficacy of GBEs for MCI.
A well designed RCT demonstrated that Ginkgo biloba extract
EGb 761 improved cognitive functioning and aspects of quality
of life in very mild MCI patients when compared with placebo
control (Grass-Kapanke et al., 2011), and another one in MCI
patients with neuropsychiatric symptoms (Gavrilova et al.,
2014). However, no primary systematic review included this
important RCT. Furthermore, a correct diagnosis is a crucial
issue in every field lacking objective/instrumental markers of
the disorder/syndrome under investigation (Halbreich, 2004).
Based on the Diagnostic and Statistical Manual (DSM)-5
of the American Psychiatric Association, cognitive decline is
divided into major and mild neurocognitive disorders (American
Psychiatric Association, 2013). The DSM-5 classification has the
advantage of covering the full range of MCI and dementia on
the one hand and the different etiologic types of neurocognitive
disorders on the other. However, the DSM-5 is not the only
classification and diagnostic system that is appropriate to
diagnose and select patients for clinical trials. A recent paper
by Hoerr and Zaudig (2016) shows that the patients enrolled
in the dementia trials meet the DSM-5 diagnostic criteria for
major neurocognitive disorders and the patients enrolled in the
recent MCI trials (as well as some older trials) meet the DSM-5
criteria for mild neurocognitive disorders. Thus, at least for the
special Ginkgo extract EGb 761 R©, there is no need to do new
trials in patients defined by the DSM-5. Further rigorous RCT on
GBEs should be performed according to appropriate diagnostic
criteria.
There is clear evidence to support efficacy of GBEs for
dementia, and the effect is dose and age-dependent. Efficacy was
only demonstrated when they were used at a high daily dose (240
mg), and efficacy was only demonstrated for the extract EGb 761.
We recommend that dementia patients with the above characters
can choose EGb 761 as a treatment. Regarding prevention
of dementia in healthy people, it should be remembered that
a lack of scientific evidence does not necessarily mean that
the treatment is ineffective (Kotsirilos, 2005). Whether healthy
patients at risk or lower doses of GBE, or Ginkgo extracts other
than EGb 761 are effective, still needs to be evaluated by rigorous
clinical trials using the best available scientific standards. The
patients should be divided into more subgroups according to
different ages, GBEs dosages, and DSM-5 classification criteria of
cognitive decline.
CONCLUSION
The interests of the public and the medical profession in the
use of GBEs for MCI and dementia have grown considerably
in recent years. Our analysis supports the efficacy of GBEs for
MCI and dementia of both the Alzheimer type and the vascular
type of dementia, and of mixed dementias. In addition, GBEs are
generally safe.
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